Amyloid imaging

International Psychogeriatrics

Volumn 23, Issue S2, 2011, Pages S41-S49

  Villemagne, Victor L ^a,b   Rowe, Christopher C ^a  

^a AUSTIN HEALTH   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Alzheimer's disease; A ; brain imaging; dementia; positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BRAIN CORTEX; EARLY DIAGNOSIS; HUMAN; METABOLISM; METHODOLOGY; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; CEREBRAL CORTEX; EARLY DIAGNOSIS; FLUORODEOXYGLUCOSE F18; HUMANS; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84856470575     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610211000895     Document Type: Review

References (49)

1. Aizenstein H. J., et al(2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65, 1509–1517.
2. Braak H. and Braak E. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging, 18, 351–357.
3. Chang C. Y. and Silverman D. H. (2004). Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease. Expert Reviews in Molecular Diagnosis, 4, 63–69.
4. Chetelat G., et al(2010). Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Annals of Neurology 67, 317–324.
5. Clark C. M., et al(2008). Biomarkers for early detection of Alzheimer pathology. Neurosignals, 16, 11–18.
6. Clark C. M., et al(2011). Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA, 305, 275–283.
7. Edison P., et al(2008). Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry, 79, 1331–1338.
8. Ellis K. A., et al(2009). The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 21, 672–687.
9. Fagan A. M., et al(2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Annals of Neurology, 59, 512–519.
10. Fodero-Tavoletti M. T., et al(2011). [18F]-THK523, a novel in vivo tau imaging ligand for Alzheimer's disease. Brain, 134, 1089–1100.
11. Ikonomovic M. D., et al(2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 131, 1630–1645.
12. Jack C. R., Jr., et al(2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurology, 9, 119–128.
13. Johansson A., et al(2008). [(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism and Related Disorders, 14, 345–347.
14. Johnson K. A., et al(2007). Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of Neurology, 62, 229–234.
15. Jureus A., et al(2010). Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. Journal of Neurochemistry, 114, 784–794.
16. Klunk W. E., et al(2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55, 306–319.
17. Klunk W. E., et al(2007). Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Journal of Neuroscience, 27, 6174–6184.
18. Masters C. L., et al(2006). Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry, 97, 1700–1725.
19. Mathis C. A., et al(2002). A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic Medical Chemistry Letters, 12, 295–298.
20. McKhann G., et al(1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939–944.
21. Morris J. C. and Price A. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience, 17, 101–118.
22. Morris J. C., et al(2010). APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Annals of Neurology, 67, 122–131.
23. Ng S., et al(2007a). Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. Journal of Nuclear Medicine, 48, 547–552.
24. Ng S. Y., et al(2007b). Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Archives of Neurology, 64, 1140–1144.
25. Ong K., et al(2010). Assessment of Aβ deposition in mild cognitive impairment with 18F-florbetaben. Alzheimer's and Dementia, 6, S26.
26. Petersen R. C. (2007). Mild cognitive impairment: current research and clinical implications. Seminars in Neurology, 27, 22–31.
27. Pike K. E., et al(2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 130, 2837–2844.
28. Rabinovici G. D., et al(2007). 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 68, 1205–1212.
29. Reiman E. M., et al(2009). Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 106, 6820–6825.
30. Rowe C. C., et al(2007). Imaging beta-amyloid burden in aging and dementia. Neurology, 68, 1718–1725.
31. Rowe C. C., et al(2008). Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94–9172, a novel PET tracer: proof of mechanism. Lancet Neurology, 7, 129–135.
32. Rowe C. C., et al(2010). Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 31, 1275–1283.
33. Sabri O., et al(2010). Florbetaben for beta-amyloid brain PET in Alzheimer's disease: results of a multicenter phase 2 trial. Alzheimer's and Dementia, 6, S70.
34. Senda M., et al(2010). Inter-ethnic comparability of pharmacokinetics of tlorbetaben (BAY 94–9172), a beta-amyloid imaging PET agent, as a basis of global development of a diagnostics for Alzheimer's disease. Alzheimer's and Dementia, 6, S48.
35. Shaw L. M., et al(2007). Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Review of Drug Discoveries, 6, 295–303.
36. Shoghi-Jadid K., et al(2002). Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 10, 24–35.
37. Smith E. E., et al(2008). Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Archives of Neurology, 65, 94–100.
38. Sperling R., et al(2009). PET imaging of beta-amyloid with florpiramine F18 (18F-AV-45): preliminary results from a phase II study of cognitively normal elderly subjects, individuals with mild cognitive impairment, and patients with a clinical diagnosis of Alzheimer's disease. Alzheimer's and Dementia, 5, P197 [abstract].
39. Tolboom N., et al(2009). Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. Journal of Nuclear Medicine, 50, 191–197.
40. Vandenberghe R., et al(2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Annals of Neurology, 68, 319–329.
41. Villemagne V. L. and Rowe C. C. (2010). Amyloid ligands for dementia. PET Clinics, 5, 33–53.
42. Villemagne V. L., et al(2006). The Abeta centric pathway of Alzheimer's disease. In Barrow C. J. and Small B. J. (eds.), Abeta Peptide and Alzheimer's Disease (pp. 5–32). London: Springer-Verlag.
43. Villemagne V. L., et al(2008a). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, 46, 1688–1697.
44. Villemagne V. L., et al(2008b). The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias. Molecular Neurobiology, 38, 1–15.
45. Villemagne V. L., et al(2009a). High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Archives of Neurology, 66, 1537–1544.
46. Villemagne V. L., et al(2009b). 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 80, 998–1001.
47. Villemagne V. L., et al(2010). 18F-Florbetaben-PET imaging in the differential diagnosis of dementia. Alzheimer's and Dementia, 6, S70–S71.
48. Villemagne V. L., et al(2011). Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Annals of Neurology, 69, 181–192.
49. Wong D. F., et al(2010). In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). Journal of Nuclear Medicine, 51, 913–920.